US Stem Cell Inc (USRM)

[Tfan15]

Thank you Gsdubb. In the body of the report in one of the very first paragraphs a gross inaccuracy is stated...that due to the 'size' of the trial, Teva/Mesoblast will be the leader in the cardiac stem field. The leader in that field of medicine, or any other for that matter, is not a result of the size of the study. It is most often which company comes to market first with its product ( first-to-class) and the results of the trial. Bioheart is years ahead in this endeavor and has shown to double the objective efficacy measurements (6MWD test) than its nearest competitor. I know the intent of your post was to show potential for the future of this technology, and you are most correct...timeline to launch and efficacy comparisons were also staggering! Wanted to mention in case anyone began feeling we were not the leader we indeed are.